Press Releases

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.

Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference Cambridge, MA, September 8, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns 19th Annual Healthcare Conference.

LEXIVA(R)/r Twice-Daily Provided Comparable Efficacy to Kaletra Twice-Daily in Treatment-Naive HIV Patients

Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor

Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior

- VX-950 Global Phase 2b Clinical Development Plan On Track -
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company, Adds Important Strengths
and Development Capabilities for VX-950 -

Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals

Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex

- PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients -

- 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -
- 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy -

- FDA Grants Fast Track Designation to VX-770 -

GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and

- Company Updates Corporate Governance Practices -

-New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks-

Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver

–– Company on Track to Achieve Clinical, Research and Corporate Objectives ––

- Vertex earns $10 million milestone payment -

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF Cambridge, MA, March 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.

--Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--